Meeting Abstract

New derivatives of 2-deoxy-D-glucose (2-DG) in the therapy of glioblastoma multiforme - preliminary studies

Volume: 11 Number: 0 June 21, 2019
  • Ewelina Siwiak *
  • Maja Sołtyka
EN

New derivatives of 2-deoxy-D-glucose (2-DG) in the therapy of glioblastoma multiforme - preliminary studies

Abstract

Tumor cells preferentially use the glycolysis process as a source of ATP regardless of the availability of oxygen (Warburg effect). GBM cells are particularly dependent on this process. A PET diagnostic test using a fluoro-labeled 2-DG derivative indicates that GBM cells accumulate 2-DG in their interior. Unfortunately, therapeutic use of 2-DG is limited due to insufficient pharmacokinetic parameters of the compound. However, a chemical modification involving the substitution of -OH groups with acetyl groups leads to an increase in 2-DG permeability across the BBB and its concentrations in GBM cells. Based on previous preliminary results using the O-acetylated 2-DG-2deoxy-3,6-di-O-acetyl-D-glucose derivative (WP1122), we assume that the new halogen (2-BG, 2-IG, 2-CG) and acetyl 2-DG derivatives will be highly cytotoxic to GBM cells. In addition, we anticipate the analysis of a new class of 2-DG derivatives, which may be modulated with ethylbutyrate and VPA, may also modulate the activity of HDAC and thus the expression of genes involved in cell apoptosis. The obtained preliminary results on the in vitro model showed that 2-DG decreases the viability of the U87 and U251 cell lines depending on the dose. The IC50 2-DG is for the following lines: U87-0.6mM, 0.5 mM (46,72h), U251-0.7mM, 0.45mM (48,72h). The percentage of apoptotic cells was evaluated by flow cytometry and cell staining with annexinV and PI. The MTT analysis of WP122 showed that the IC50 is in the cells of U87 line-1.5mM, 0.8mM (48,72h), U2511.25mM, 0.8mM (48,72h). The MTT analyzes of the effects of HDIs: NaBt and VPA determined the IC50 for NaBt: U87-1.48mM, 0.95mM (48,72h), U251-2.1mM, 2mM (48,72h); for VPA: U87-6.2mM, 6.0mM (48,72h), U251-5.3mM, 4.2mM (48,72h). Preliminary studies in the analysis of halo-derivatives interaction with hexokinase allowed to develop a model of expression and obtain a recombinant hexokinase protein, which will then be used for crystallographic analyzes. 

Keywords

References

  1. Kiesel V, Hursting S, Teegarden D. Differential Response to 1,25-dihydroxyvitamin D in Metastatic and Non-Metastatic Breast Cancer Cell Lines in Hypoxia (P05-006-19). Curr Dev Nutr. 2019 Jun 13;3(Suppl 1). pii: nzz030.P05-006-19.

Details

Primary Language

English

Subjects

Biochemistry and Cell Biology (Other)

Journal Section

Meeting Abstract

Authors

Ewelina Siwiak * This is me
Poland

Maja Sołtyka This is me
Poland

Publication Date

June 21, 2019

Submission Date

May 9, 2019

Acceptance Date

June 13, 2019

Published in Issue

Year 2019 Volume: 11 Number: 0

APA
Siwiak, E., & Sołtyka, M. (2019). New derivatives of 2-deoxy-D-glucose (2-DG) in the therapy of glioblastoma multiforme - preliminary studies. Journal of Cellular Neuroscience and Oxidative Stress, 11, 21-21. https://doi.org/10.37212/jcnos.584722
AMA
1.Siwiak E, Sołtyka M. New derivatives of 2-deoxy-D-glucose (2-DG) in the therapy of glioblastoma multiforme - preliminary studies. J Cell Neurosci Oxid Stress. 2019;11:21-21. doi:10.37212/jcnos.584722
Chicago
Siwiak, Ewelina, and Maja Sołtyka. 2019. “New Derivatives of 2-Deoxy-D-Glucose (2-DG) in the Therapy of Glioblastoma Multiforme - Preliminary Studies”. Journal of Cellular Neuroscience and Oxidative Stress 11 (June): 21-21. https://doi.org/10.37212/jcnos.584722.
EndNote
Siwiak E, Sołtyka M (June 1, 2019) New derivatives of 2-deoxy-D-glucose (2-DG) in the therapy of glioblastoma multiforme - preliminary studies. Journal of Cellular Neuroscience and Oxidative Stress 11 21–21.
IEEE
[1]E. Siwiak and M. Sołtyka, “New derivatives of 2-deoxy-D-glucose (2-DG) in the therapy of glioblastoma multiforme - preliminary studies”, J Cell Neurosci Oxid Stress, vol. 11, pp. 21–21, June 2019, doi: 10.37212/jcnos.584722.
ISNAD
Siwiak, Ewelina - Sołtyka, Maja. “New Derivatives of 2-Deoxy-D-Glucose (2-DG) in the Therapy of Glioblastoma Multiforme - Preliminary Studies”. Journal of Cellular Neuroscience and Oxidative Stress 11 (June 1, 2019): 21-21. https://doi.org/10.37212/jcnos.584722.
JAMA
1.Siwiak E, Sołtyka M. New derivatives of 2-deoxy-D-glucose (2-DG) in the therapy of glioblastoma multiforme - preliminary studies. J Cell Neurosci Oxid Stress. 2019;11:21–21.
MLA
Siwiak, Ewelina, and Maja Sołtyka. “New Derivatives of 2-Deoxy-D-Glucose (2-DG) in the Therapy of Glioblastoma Multiforme - Preliminary Studies”. Journal of Cellular Neuroscience and Oxidative Stress, vol. 11, June 2019, pp. 21-21, doi:10.37212/jcnos.584722.
Vancouver
1.Ewelina Siwiak, Maja Sołtyka. New derivatives of 2-deoxy-D-glucose (2-DG) in the therapy of glioblastoma multiforme - preliminary studies. J Cell Neurosci Oxid Stress. 2019 Jun. 1;11:21-. doi:10.37212/jcnos.584722